Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 12.

Curioni-Fontecedro, Alessandra; Ickenberg, C; Franzen, D; Rogler, Gerhard; Burger, Irene A; van den Broek, M (2017). Diffuse pseudoprogression in a patient with metastatic non-small-cell lung cancer treated with Nivolumab. Annals of Oncology, 28(8):2040-2041.

van den Broek, M; von Boehmer, L; Knuth, A (2010). Developments in cancer immunotherapy. Digestive Diseases, 28(1):51-56.

Keller, A M; Schildknecht, A; Xiao, Y; van den Broek, M; Borst, J (2008). Expression of costimulatory ligand CD70 on steady-state dendritic cells breaks CD8+ T cell tolerance and permits effective immunity. Immunity, 29(6):934-946.

Khan, S; van den Broek, M; Schwarz, K; de Giuli, R; Diener, P A; Groettrup, M (2001). Immunoproteasomes largely replace constitutive proteasomes during an antiviral and antibacterial immune response in the liver. Journal of Immunology, 167(12):6859-6868.

Khan, S; de Giuli, R; Schmidtke, G; Bruns, M; Buchmeier, M; van den Broek, M; Groettrup, M (2001). Cutting edge: neosynthesis is required for the presentation of a T cell epitope from a long-lived viral protein. Journal of Immunology, 167(9):4801-4804.

Groettrup, M; van den Broek, M; Schwarz, K; Macagno, A; Khan, S; de Giuli, R; Schmidtke, G (2001). Structural plasticity of the proteasome and its function in antigen processing. Critical Reviews in Immunology, 21(4):339-358.

Schwarz, K; de Giuli, R; Schmidtke, G; Kostka, S; van den Broek, M; Kim, K B; Crews, C M; Kraft, R; Groettrup, M (2000). The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses. Journal of Immunology, 164(12):6147-6157.

Wirth, S; van den Broek, M; Frossard, C P; Hügin, A W; Leblond, I; Pircher, H; Hauser, C (2000). CD8(+) T cells secreting type 2 lymphokines are defective in protection against viral infection. Cellular Immunology, 202(1):13-22.

Schwarz, K; van den Broek, M; de Giuli, R; Seelentag, W W; Shastri, N; Groettrup, M (2000). The use of LCMV-specific T cell hybridomas for the quantitative analysis of MHC class I restricted antigen presentation. Journal of Immunological Methods, 237(1-2):199-202.

Betz, U A; Bloch, W; van den Broek, M; Yoshida, K; Taga, T; Kishimoto, T; Addicks, K; Rajewsky, K; Müller, W (1998). Postnatally induced inactivation of gp130 in mice results in neurological, cardiac, hematopoietic, immunological, hepatic, and pulmonary defects. Journal of Experimental Medicine, 188(10):1955-1965.

Gallimore, A; Schwarz, K; van den Broek, M; Hengartner, H; Groettrup, M (1998). The proteasome inhibitor lactacystin prevents the generation of an endoplasmic reticulum leader-derived T cell epitope. Molecular Immunology, 35(10):581-91.

Moskophidis, D; Battegay, M; van den Broek, M; Laine, E; Hoffmann-Rohrer, U; Zinkernagel, R M (1995). Role of virus and host variables in virus persistence or immunopathological disease caused by a non-cytolytic virus. Journal of General Virology, 76/ 2:381-391.

This list was generated on Wed Apr 25 09:37:33 2018 CEST.